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Abstract
Background: Understanding co-receptor tropism of HIV-1 strains circulating in India will provide key analytical
leverage for assessing the potential usefulness of newer antiretroviral drugs such as chemokine co-receptor
antagonists among Indian HIV-infected populations. The objective of this study was to determine using in silico
methods, HIV-1 tropism among a large number of Indian isolates both from primary clinical isolates as well as from
database-derived sequences.
Results: R5-tropism was seen in 96.8% of a total of 1045 HIV-1 subtype C Indian sequences. Co-receptor prediction
of 15 primary clinical isolates detected two X4-tropic strains using the C-PSSM matrix. R5-tropic HIV-1 subtype C V3
sequences were conserved to a greater extent than X4-tropic strains. X4-tropic strains were obtained from subjects
who had a significantly longer time since HIV diagnosis (96.5 months) compared to R5-tropic strains (20.5 months).
Conclusions: High prevalence of R5 tropism and greater homogeneity of the V3 sequence among HIV-1 subtype
C strains in India suggests the potential benefit of CCR5 antagonists as a therapeutic option in India.
Background
After the discovery of the CD4 molecule as the major
cellular receptor for HIV entry [1,2], multiple studies
suggested the presence of a secondary cellular receptor
for HIV entry into the human CD4 cell [3,4]. These co-
receptors, particularly the chemokine receptors CCR5
and CXCR4, have been the subject of much research
attempting to elucidate viral entry mechanisms, disease
progression, antiretroviral therapy and vaccine develop-
ment. Based on co-receptor usage, viral strains are clas-
sified into R5-tropic (those that use CCR5 for cellular
entry), X4-tropic (those that use CXCR4) and dual
tropic strains (those that use both co-receptors) [5].
Co-receptor tropism of individual viral strains can be
delineated using reporter cells expressing different core-
ceptors; however such cell-based assays are labor-inten-
sive, expensive and not appropriate for high throughput
screening [6]. As an alternative, in silico strategies using
computer simulation and bioinformatics have been
developed to predict viral co-receptor usage from env
gene sequence information [5-7]. Of late, the in silico
approaches have been gaining popularity given the sim-
plicity of this strategy and the fact that env sequences
are increasingly becoming available globally.
The simplest method used for delineating HIV-1 trop-
ism is known as the ‘charge rule’ [8], which relies on the
charge of amino acids at positions 11 or 25 within the V3
loop when aligned against a consensus. Presence of
positively charged amino acids (i.e. arginine, lysine, or
histidine) in these positions typically is indicative of X4-
tropism, while presence of other amino acid residues is
associated with R5 phenotype [9]. Currently a number of
tools are available online to predict the co-receptor usage
on the basis of the V3 sequence. Such tools include
among others, (i) Geno2Pheno which predicts whether the
corresponding virus is capable of using CXCR4 as a co-
receptor (R5/X4 or X4 variants) or not (R5 variants) [10],
(ii) the distant segments (ds)Kernel which include relative
positional information of segments in a string of symbols
which detects R5-, X4- and R5X4-tropic strains[11], and
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any medium, provided the original work is properly cited.(iii) WebPSSM using CPSSM, a genotypic predictor based
on position-specific scoring matrices (PSSM) which
detects R5- or X4- tropic strains specially designed and
validated for HIV-1 subtype C [12]. Dual-tropic strains in
C-PSSM are grouped with the X4- data set [12]. Till date,
molecular epidemiological information from India has
indicated that > 96% HIV-1 circulating strains are HIV-1
subtype C (Geographic search interface, Los Alamos data-
base, accessed on February 2010) [13]. While X4-tropic
HIV-1 subtype C strains have been widely reported from
Africa [14-16], the presence of CXCR4 as a co-receptor to
facilitate entry into the host cell is uncommon among
Indian subtype C strains [17,18]. R5-tropic viruses consti-
tute by far the predominant strains in India although
recent reports indicate the occasional presence of HIV-1
subtype C X4-tropic strains [19-21].
We aimed to characterize co-receptor tropism of HIV-
1 subtype C strains isolated from a clinical cohort in
southern India, using three different online bioinfor-
matics tools. Furthermore, we aimed to validate this
strategy and expand our understanding of co-receptor
tropism preference among Indian strains by extending
this analysis to a total of 1030 V3 sequences of Indian
origin available at Los Alamos databank.
Methods
Study population and sample collection
A single peripheral blood sample was collected from 15
ART-naïve patients (10 males, 5 females) attending the
Infectious Disease Clinic at St. John’s Medical Hospital,
Bangalore, between 1 and 30 November 2009. Patient
characteristics are described in Table 1. Routine CD4
count was performed using a dual-platform flow cyt-
ometer (FACSCalibur, BD, USA). Genomic DNA from
whole blood was extracted using a commercial kit
(QIAamp Blood DNA kit, Qiagen, Germany).
Polymerase chain reaction and sequencing
The env gene portion encoding the V3-V5 region was
amplified by nested polymerase chain reaction (PCR)
from whole blood genomic DNA using iNtRON Taq
Polymerase (Intron Biotech, South Korea). Primers were
designed based on a consensus Indian sequence and
modified from previously published reports [22,23]. The
first round of PCR was carried out with a forward
primer, FP1: 5-CACCGGCTTAGGCATCTCCTATGG-
CAGGAAGAA-3 and reverse primer RP1: 5-
TAACCCTTCCAGGTACCCCCTTTTCTTTTA-3. The
nested PCR was carried out with the forward primer,
FP2: 5′-tgtaaaacgacggccagtCTGTTAAATGGCAGTC-
TAGC and reverse primer, RP2: 5′-caggaaacagctatgacc-
CACTTCTCCAATTGTCCCTCA. Primers FP2 and RP2
contain the M13 universal primer sequence (lower case),
which was used for population based sequencing.
Subtyping
HIV subtyping was carried out using three different tools
i.e. REGA subtyping tools v2.0 http://www.bioafrica.net/
rega-genotype/html/subtypinghiv.html[24], NCBI Viral
Genotyping tools http://www.ncbi.nlm.nih.gov/projects/
genotyping/formpage.cgi[25] and RIP 3.0 http://www.hiv.
lanl.gov/content/sequence/RIP/RIP.html[26].
Indian V3 sequence and co-receptor prediction
Sequences from our primary clinical isolates (n = 15)
were pooled with 1030 Indian V3 sequences (additional
file 1; accession numbers and sequence information)
available from the Los Alamos database accessed on 7
Feb 2010. All available HIV-1 subtype C V3 sequences
(n = 1114) were downloaded. Sequences containing a
premature stop codon (n = 84) were excluded from the
study. In all, 1045 sequences were analyzed in silico for
co-receptor tropism using three different tools; (i) C-
PSSM http://indra.mullins.microbiol.washington.edu/
webpssm/, (ii) Geno2pheno [co-receptor] http://corecep-
tor.bioinf.mpi-inf.mpg.de/ and (iii) (ds)Kernel http://
genome.ulaval.ca/hiv-dskernel/. To compare V3 charac-
teristics of the R5 and X4 tropic strains, the consensus
s e q u e n c e so fR 5a n dX 4t r o p i cs t r a i n sd e t e c t e di nC -
PSSM were obtained using WebLogo http://weblogo.
berkeley.edu/logo.cgi and consensus maker tool present
in Los Alamos database http://www.hiv.lanl.gov/content/
sequence/CONSENSUS/consensus.html. The mutation
patterns of the cohort V3 loop sequences were com-
pared with the consensus HIV-1 subtype C sequence
and presented as additional file 2.
Ethical aspects
This study was approved by the Institutional Ethical
Review Board of St. John’s Medical College and Hospi-
tal. Written informed consent was obtained from each
participant prior to sample collection.
Results
Subtyping
All the 15 clinical isolates were detected as HIV-1 Subtype
C; using three different subtyping tools, REGA subtyping
tools v 2, NCBI Viral Genotyping tools and RIP 3.
Co-receptor tropism
Table 1 summarizes the predicted co-receptor tropism
of each of the individual viral strains derived from our
clinical cohort. While all the three tools predicted 13
out of the 15 viruses to be R5-tropic, there was dis-
agreement among them with respect to two viral strains.
The viral strain SJNAHS04 was predicted to be an X4
virus by C-PSSM while the other two tools characterized
it to be a R5 virus. Similarly, the strain SJNAHS13 was
predicted to be an R5 virus by (ds)Kernel while the
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reliable the three bioinformatics tools were in predicting
co-receptor tropism of subtype C strains, we applied
each of these tools to 1030 Indian env V3 sequences
available at the Los Alamos database. This analysis con-
firmed a high magnitude of R5-tropism in the Indian
env sequences predicted by all the three tools, 97%, 99%
and 99.6% of R5-tropic sequences by CPSSM, Geno2-
Pheno and (ds) Kernel, respectively (Figure 1). As multi-
ple sequences may be derived from the same patient, a
second analysis was done after eliminating sequences
that were derived from the same individual, and the
result was similar to that obtained when all included
sequences were analyzed.
The score in C-PSSM used for coreceptor tropism
prediction was previously validated using sequences of
the known syncytium inducing (SI) phenotypes on the
MT2 cell line [12]. C-PSSM score for SJNAHS04
(known history of HIV positivity > 5 years) was -16.09
and SJNAHS13 (known history of HIV positivity > 10
years) was -19.35; both were well above the prediction
cutoff of -21.64 for X4-tropic viruses [12]. The remain-
ing isolates characterized to be R5-tropic were obtained
from subjects with a recent history of HIV diagnosis
within the past 5 years. The mean duration since detec-
tion of HIV-1 infection was longer for X4-tropic strains
compared to R5-tropic strains (96.5 months and 20.5
months respectively), although only 2 X4-tropic strains
were available for this analysis.
Sequence characteristics of Indian V3 sequence
Given that the emergence of X4 viruses is correlated
with disease progression in subtype B infection, and
that, although rare, several dual-tropic and X4-tropic
viruses have been reported in subtype C from within
and outside India, we sought to understand the rela-
tive magnitude of genetic variation between the V3
amino acid sequences of the predicted X4- and R5-
tropic strains of the Indian origin. Consensus
sequence logos for V3 amino acid sequences of 1012
Table 1 Patient demographic details and predicted HIV-1 subtype C co-receptor tropism
Patient demographic details HIV-1 Co-receptor Tropism
No Patient ID Age Sex Time since sero-diagnosis (months) CD4 Count
(cells/mm
3)
Disease Stage WebPSSM
(C-PSSM)
Geno2pheno (ds)Kernel
Score Tropism
1. SJNAHS01 33 M 43 223 2
nd -29.39 R5 R5 R5
2. SJNAHS02 53 F 4 247 2
nd -29.97 R5 R5 R5
3. SJNAHS03 30 M 46 173 2
nd -23.28 R5 R5 R5
4. SJNAHS04 37 M 63 538 1
st -16.09 X4 R5 R5
5. SJNAHS06 36 F 1 122 3
rd -23.32 R5 R5 R5
6. SJNAHS07 26 F 1 384 1
st -29.97 R5 R5 R5
7. SJNAHS09 38 F 1 356 3
rd -25.74 R5 R5 R5
8. SJNAHS10 38 M 105 438 3
rd -25.74 R5 R5 R5
9. SJNAHS11 26 M 15 594 1
st -29.39 R5 R5 R5
10. SJNAHS12 38 M 22 59 1
st -25.74 R5 R5 R5
11. SJNAHS13 36 M 130 77 1
st -19.35 X4 X4 R5
12. SJNAHS16 39 M 1 13 4
th -29.08 R5 R5 R5
13. SJNAHS17 36 F 1 75 1
st -29.05 R5 R5 R5
14. SJNAHS18 60 M 1 99 4
th -22.37 R5 R5 R5
15. SJNAHS19 40 M 2 200 1
st -22.37 R5 R5 R5
Patient demographic characteristics and predicted co-receptor tropism in the South Indian cohort. CD4 count represents the value at the time of study. Co-
receptor tropism was detected using C-PSSM, Geno2pheno and (ds)Kernel method. In C-PSSM a score of above -21.64 was considered predictive of X4-tropism.
Disease stage according to WHO classification has been mentioned.
Figure 1 In silico viral tropism analysis. Prediction of the viral co-
receptor tropism using three different online tools C-PSSM,
Geno2Pheno and (ds)Kernal. The analysis is applied to 15 primary
viral isolates and a total 1030 V3 loop sequences derived from the
Los Alamos database.
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WebLogo v.3 http://weblogo.berkeley.edu/logo.cgi.
This analysis identified a high degree of conservation
within the key amino acid residues of V3 loop of the
R5-tropic (Figure 2A), but not X4-tropic strains
(Figure 2B). The V3 loop amino acid residues of the
X4-tropic strains were highly variable (Figure 2B). An
analysis of the V3 sequences of Indian subtype C,
subtype B and subtype A/A1 irrespective of co-recep-
tor tropism detected greater magnitude of sequence
diversity in subtype B and A/A1 compared to V3
sequences of Indian HIV-1 subtype C (see additional
file 3).
Discussion
The overwhelming majority of Indian HIV-1 subtype C
strains, 96.8% (1012 out of 1045) were predicted to be
R5-tropic according to C-PSSM analysis. There were
discrepancies in predicting HIV-1 subtype C X4-trop-
ism as most of the tools were developed for HIV-1
subtype B strains. The C-PSSM represents an improve-
ment over currently available methods for predicting
X4-viruses in subtype C populations; this method has
an estimated sensitivity of 81.8% and specificity of
93.3%, values considerably superior compared to other
tools [8]. Investigators studying co-receptor tropism
prediction among African subtype C strains reported
100% concordance of C-PSSM with phenotypic assay
in detecting CXCR4 [12]. Our data supports the predo-
minance of R5 phenotype in subtype C infected
patients in India. Our data also revealed a correlation
between X4-tropism and the duration since first diag-
nosis although this is to be interpreted with caution
given that only 2 X4-tropic strains were studied. Both
patients harboring probableX 4 - t r o p i cv i r u sw e r ed i a g -
nosed with HIV-1 infection for longer than 5 years.
Two previous reports of X4-tropic HIV-1 subtype C
viruses from India have not commented on the length
of infection [19,20]. The presence of X4-tropic strains
is well known to be significantly associated with longer
duration of HIV infection [27]. Variations at position
16 and 18 of the V3 loop in R5 viruses have been
reported to lead to X4 tropism [28]. In all the Indian
R5 tropic HIV-1 subtype C sequences including cohort
Figure 2 Consensus sequence logos of the Indian V3 sequences. A. HIV-1 subtype C CCR5-tropic strains (n = 1012), B. Subtype C CXCR4-
tropic strains (n = 33). The overall height of the stack indicates the sequence conservation at that position, while the height of the symbols
within the stack indicates the relative frequency of each amino acid at that position.
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was significantly conserved, but in Indian X4 tropic
strains, the 18th position was variable (Figure 2B). The
overall conserved nature of HIV-1 subtype C V3
sequence may reduce the possibility of co-receptor
switch in subtype C viruses and may partially explain
the low prevalence of X4-tropic strains. An additional
contributory factor for the high prevalence of R5-tro-
pic strains may be the presence of a large pool of
CCR5 positive CD4 cells in the Indian population
which allows for the R5-strains to have improved repli-
cation fitness [29]. CCR5 expression on CD4+ cells of
HIV-1 infected individuals is higher among the Indian
population (26.8%) [29] compared to the population in
the USA (13.2%) [30]. Two European studies showed
varying levels of expression of CCR5 on CD4+ cells
from HIV-infected individuals; 28% in Netherlands
[31] and 17% in Italy [32].
The implementation of antiretroviral therapy (ART) in
resource-limited settings requires use of standard first-
and second-line therapies. CCR5 receptor antagonists
such as maraviroc is a potential future option for sec-
ond-line therapy in populations where R5-tropic strains
predominate [33,34]. The high proportion of R5-tropic
strains and decreased evidence of co-receptor switch in
HIV-1 subtype C viruses in India support the proposi-
tion that CCR5-antagonists may be promising drugs for
future HIV treatment although concerns about potential
overgrowth of X4-tropic strains need to be adequately
addressed.
Conclusions
The present study, the first of its kind from India
where a large number of env sequences were sub-
jected to in silico co-receptor prediction analysis,
revealed high prevalence of R5-tropism and greater
homogeneity within the V3 loop sequences of HIV-
1 subtype C Indian strains. Although prediction
tools may not entirely substitute experimental eva-
luation, the simplicity of in silico strategies high-
lighted in this study can be a major advantage for
coreceptor tropism prediction in resource-con-
strained settings. Furthermore, our findings also
allude to the possibility of including CCR5 antago-
nists to the anti-retroviral repertoire with additional
necessary precautions. The therapeutic implications
of our findings are of global relevance and will
facilitate further research on HIV-1 co-receptor
usage and viral diversity.
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